Print

Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research  
11/18/2010 12:22:09 PM

SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, announced today the appointment of Sean Stevens, Ph.D., as vice president, research. Reporting to Larry L. Green, Ph.D., chief executive officer of Ablexis, Dr. Stevens will lead the development and assist in the ongoing commercialization of the AlivaMab Mouse platform.
//-->